Drug Trial Radar · NCT00000802
A Randomized, Comparative Study of Daily Dapsone and Daily Atovaquone for Prophylaxis Against PCP in HIV-Infected Patients Who Are Intolerant of Trimethoprim and/or Sulfonamides
Last checked: Nov 20, 2026Latest source record: Nov 4, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
700
Actual
Start
Not stated
Primary completion
Not stated
Study completion Jul 1997
Sponsor
- Sponsor type
- NIH
- First posted
- Aug 31, 2001
Design
- Study type
- Interventional
- Phase
- Phase 3
- Model
- Parallel
- Primary purpose
- Treatment
- Who can join
- All sexes, from 13 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To compare the efficacy and safety of dapsone versus atovaquone in preventing or delaying the onset of histologically proven or probable Pneumocystis carinii pneumonia in HIV-infected patients with CD4 counts \<= 200 cells/mm3 or \<= 15 percent of the total lymphocyte count who are intolerant to trimethoprim and/or sulfonamides. Trimethoprim/sulfamethoxazole (TMP/SMX), which is effective for secondary PCP prophylaxis, is associated with allergic manifestations and side effects that limit its use. Patients who are intolerant of TMP/SMX require an effective alternative. Dapsone and atovaquone have both shown promise as PCP prophylactic agents.
Conditions
- Pneumonia, Pneumocystis Carinii
- HIV Infections
Interventions
AtovaquoneDrug
DapsoneDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
44 sites in 2 countries. Site status is shown where the registry gives one.
Alabama Therapeutics CRS
Birmingham, Alabama
USC CRS
Los Angeles, California
Stanford CRS
Palo Alto, California
Ucsd, Avrc Crs
San Diego, California
Ucsf Aids Crs
San Francisco, California
Santa Clara Valley Med. Ctr.
San Jose, California
San Mateo County AIDS Program
San Mateo, California
Harbor-UCLA Med. Ctr. CRS
Torrance, California
University of Colorado Hospital CRS
Aurora, Colorado
Howard University Hosp., Div. of Infectious Diseases, ACTU
Washington D.C., District of Columbia
Univ. of Miami AIDS CRS
Miami, Florida
Emory Univ. Hemophilia Program Office
Atlanta, Georgia
Queens Med. Ctr.
Honolulu, Hawaii
Univ. of Hawaii at Manoa, Leahi Hosp.
Honolulu, Hawaii
Northwestern University CRS
Chicago, Illinois
Cook County Hosp. CORE Ctr.
Chicago, Illinois
Rush Univ. Med. Ctr. ACTG CRS
Chicago, Illinois
Weiss Memorial Hosp.
Chicago, Illinois
Indiana Univ. School of Medicine, Infectious Disease Research Clinic
Indianapolis, Indiana
Univ. of Iowa Healthcare, Div. of Infectious Diseases
Iowa City, Iowa
Johns Hopkins Adult AIDS CRS
Baltimore, Maryland
Bmc Actg Crs
Boston, Massachusetts
Beth Israel Deaconess - East Campus A0102 CRS
Boston, Massachusetts
Massachusetts General Hospital ACTG CRS
Boston, Massachusetts
Hennepin County Med. Ctr., Div. of Infectious Diseases
Minneapolis, Minnesota
University of Minnesota, ACTU
Minneapolis, Minnesota
St. Louis ConnectCare, Infectious Diseases Clinic
St Louis, Missouri
Washington U CRS
St Louis, Missouri
Univ. of Nebraska Med. Ctr., Durham Outpatient Ctr.
Omaha, Nebraska
SUNY - Buffalo, Erie County Medical Ctr.
Buffalo, New York
Beth Israel Med. Ctr. (Mt. Sinai)
New York, New York
NY Univ. HIV/AIDS CRS
New York, New York
Univ. of Rochester ACTG CRS
Rochester, New York
Unc Aids Crs
Chapel Hill, North Carolina
Carolinas HealthCare System, Carolinas Med. Ctr.
Charlotte, North Carolina
Regional Center for Infectious Disease, Wendover Medical Center CRS
Greensboro, North Carolina
Wake County Health and Human Services CRS
Raleigh, North Carolina
Univ. of Cincinnati CRS
Cincinnati, Ohio
Case CRS
Cleveland, Ohio
MetroHealth CRS
Cleveland, Ohio
Showing 40 of 44 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.